Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: March 10, 2026
Reporting Period: Fourth quarter and full year ended December 31, 2025.
This filing serves as a notification that the Company issued a press release detailing its financial results for the specified period. The full text of the press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the fourth quarter and full year ended December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The document explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are absent from the 8-K body text.
- Verify the specific revenue and net loss figures for Q4 and full-year 2025.
- Check the press release for updated cash runway and liquidity positions.
- Confirm any clinical trial milestones or regulatory updates mentioned in the full press release.
- Review the "Forward-Looking Statements" section in the press release for updated guidance.